Pharmaceutical Business review

Merdarex’ Q2 Revenue Increases

Medarex has posted net loss for the quarter ended June 30, 2009 at $29.2 million, or $0.23 per share, as compared to a net loss of $53.1 million, or $0.42 per share, for the same period previous year. For the six month period, the net income was $77.8 million, or $0.60 per share, as compared to $50.2 million, or $0.39 per share for the same period previous year.

Medarex’s net loss on a non-GAAP basis for the quarter ended June 30, 2009 was $36.3 million, or $0.28 per share.

Total revenues for the quarter was reported at $19.5 million, as compared to $10 million for the second quarter of the prior year. The total revenue for the six month period was $30.38 million, as compared to $21.96 million for the same period a year ago.